| Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation G Helmlinger, F Yuan, M Dellian, RK Jain Nature medicine 3 (2), 177-182, 1997 | 2098 | 1997 |
| Solid stress inhibits the growth of multicellular tumor spheroids G Helmlinger, PA Netti, HC Lichtenbeld, RJ Melder, RK Jain Nature biotechnology 15 (8), 778-783, 1997 | 1080 | 1997 |
| Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018 | 607 | 2018 |
| Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism G Helmlinger, A Sckell, M Dellian, NS Forbes, RK Jain Clinical Cancer Research 8 (4), 1284-1291, 2002 | 553 | 2002 |
| Effects of pulsatile flow on cultured vascular endothelial cell morphology G Helmlinger, RV Geiger, S Schreck, RM Nerem | 419 | 1991 |
| Formation of endothelial cell networks G Helmlinger, M Endo, N Ferrara, L Hlatky, RK Jain Nature 405 (6783), 139-141, 2000 | 232 | 2000 |
| Calcium responses of endothelial cell monolayers subjected to pulsatile and steady laminar flow differ G Helmlinger, BC Berk, RM Nerem American Journal of Physiology-Cell Physiology 269 (2), C367-C375, 1995 | 192 | 1995 |
| A mechanistic tumor penetration model to guide antibody drug conjugate design C Vasalou, G Helmlinger, B Gomes PloS one 10 (3), e0118977, 2015 | 125 | 2015 |
| Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model Y Kosinsky, SJ Dovedi, K Peskov, V Voronova, L Chu, H Tomkinson, ... Journal for immunotherapy of cancer 6 (1), 17, 2018 | 121 | 2018 |
| Pulsatile and steady flow-induced calcium oscillations in single cultured endothelial cells G Helmlinger, BC Berk, RM Nerem Journal of vascular research 33 (5), 360-369, 1996 | 109 | 1996 |
| Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis KM Hallow, Y Gebremichael, G Helmlinger, V Vallon American Journal of Physiology-Renal Physiology 312 (5), F819-F835, 2017 | 108 | 2017 |
| Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients M Dellian, G Helmlinger, F Yuan, RK Jain British journal of cancer 74 (8), 1206-1215, 1996 | 101 | 1996 |
| Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart D Bottino, RC Penland, A Stamps, M Traebert, B Dumotier, A Georgieva, ... Progress in biophysics and molecular biology 90 (1-3), 414-443, 2006 | 78 | 2006 |
| Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data KM Hallow, PJ Greasley, G Helmlinger, L Chu, HJ Heerspink, DW Boulton American Journal of Physiology-Renal Physiology 315 (5), F1295-F1306, 2018 | 74 | 2018 |
| Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs A Kuttler, T Dimke, S Kern, G Helmlinger, D Stanski, LA Finelli Journal of pharmacokinetics and pharmacodynamics 37 (6), 629-644, 2010 | 73 | 2010 |
| Quantitative systems pharmacology: an exemplar model‐building workflow with applications in cardiovascular, metabolic, and oncology drug development G Helmlinger, V Sokolov, K Peskov, KM Hallow, Y Kosinsky, V Voronova, ... CPT: pharmacometrics & systems pharmacology 8 (6), 380-395, 2019 | 71 | 2019 |
| A physiology-based model of bile acid distribution and metabolism under healthy and pathologic conditions in human beings V Voronova, V Sokolov, A Al-Khaifi, S Straniero, C Kumar, K Peskov, ... Cellular and molecular gastroenterology and hepatology 10 (1), 149-170, 2020 | 56 | 2020 |
| Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis B Shulgin, Y Kosinsky, A Omelchenko, L Chu, G Mugundu, S Aksenov, ... Oncoimmunology 9 (1), 1748982, 2020 | 52 | 2020 |
| Differentiating the sodium‐glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling V Sokolov, T Yakovleva, L Chu, W Tang, PJ Greasley, S Johansson, ... CPT: Pharmacometrics & Systems Pharmacology 9 (4), 222-229, 2020 | 43 | 2020 |
| Quantitative mechanistic modeling in support of pharmacological therapeutics development in immuno-oncology K Peskov, I Azarov, L Chu, V Voronova, Y Kosinsky, G Helmlinger Frontiers in immunology 10, 924, 2019 | 40 | 2019 |
